NEW YORK, May 9, 2014 /PRNewswire/ -- Harwood Feffer
LLP (www.hfesq.com) is investigating potential claims against the
board of directors of Chelsea Therapeutics International, Ltd.
("Chelsea" or the "Company") (NASDAQ: CHTP) concerning the proposed
acquisition of the Company by H. Lundbeck
("Lundbeck").
Under the terms of the transaction, Lundbeck will acquire
Chelsea for approximately $658
million. Chelsea shareholders will receive
$6.44 in cash per share and
contingent value rights that could pay up to $1.50.
Our investigation concerns whether the Chelsea board of
directors is fulfilling its fiduciary duties, maximizing the value
of the Company, disclosing all material benefits and costs, and
obtaining full and fair consideration for Company
shareholders.
If you own Chelsea shares and wish to discuss this matter with
us, or have any questions concerning your rights and interests with
regard to this matter, please contact:
Benjamin I. Sachs-Michaels,
Esq.
Robert I. Harwood, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the firm.
Attorney Advertising © 2014 Harwood Feffer LLP. The law firm
responsible for this advertisement is Harwood Feffer LLP
(www.hfesq.com). Prior results do not guarantee or predict a
similar outcome with respect to any future matter.
Logo -
http://photos.prnewswire.com/prnh/20120215/MM54604LOGO
SOURCE Harwood Feffer LLP